Patents by Inventor Jean-François Prost

Jean-François Prost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • Publication number: 20200148777
    Abstract: The present invention relates to a glyco-engineered Fc fragment-bearing compound for its use as an immunosuppression inhibitor in the treatment of a cancer-associated immunosuppression. The invention further relates to a pharmaceutical composition comprising at least this glyco-engineered Fc fragment-bearing compound.
    Type: Application
    Filed: May 29, 2018
    Publication date: May 14, 2020
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Houcine BOUGHERARA, Emmanuel DONNADIEU
  • Patent number: 10509035
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 17, 2019
    Assignee: GAMAMABS PHARMA SA
    Inventors: Olivier Dubreuil, Jean-Marc Barret, Jean-François Prost, Delphine Desigaud
  • Publication number: 20190367625
    Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 5, 2019
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Olivier DUBREUIL, André NICOLAS, Didier MESURE
  • Publication number: 20180155433
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 7, 2018
    Inventors: Thierry CHARDÈS, Olivier DUBREUIL, André PELEGRIN, Christel LARBOURET, Jean-François PROST, Jean-Marc BARRET, Stéphane DEGOVE
  • Patent number: 9873745
    Abstract: The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: January 23, 2018
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christophe De Romeuf, Christine Gaucher, Jean-Luc Teillaud, Jean-Francois Prost
  • Publication number: 20170035903
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 9, 2017
    Inventors: OLIVIER DUBREUIL, JEAN-MARC BARRET, JEAN-FRANÇOIS PROST, DELPHINE DESIGAUD
  • Publication number: 20160060350
    Abstract: The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of Fc?RIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma.
    Type: Application
    Filed: August 17, 2015
    Publication date: March 3, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christophe DE ROMEUF, Christine GAUCHER, Jean-Luc TEILLAUD, Jean-Francois PROST
  • Patent number: 9234045
    Abstract: The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of Fc?RIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: January 12, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christophe De Romeuf, Christine Gaucher, Jean-Luc Teillaud, Jean-François Prost
  • Publication number: 20130259801
    Abstract: A method for purifying serum amyloid P protein from fresh unfrozen plasma, includes recalcifying the fresh unfrozen plasma and separation by phenyl-type hydrophobic interaction chromatography. The serum amyloid P protein is also obtainable by the method and the use thereof for therapeutic treatment purposes. A method for determining amyloid deposits in a tissue or organ of a subject is also provided.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 3, 2013
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Catherine Chenou, Jean-François Prost
  • Publication number: 20090175789
    Abstract: The present invention relates to a monoclonal antibody raised against the human LDL (Low Density Lipoprotein) receptor, binding to the peptide corresponding to amino acids 195-222 (SEQ ID NO: 1) in the peptide sequence for the human LDL receptor; to the use thereof as a drug; to a pharmaceutical composition containing this antibody; and to the use thereof in immunohistochemical analyses of cancerous, healthy, or cirrhotic tissues, in Western-Blot or ELISA analyses, or in in vivo quantification tests.
    Type: Application
    Filed: July 25, 2006
    Publication date: July 9, 2009
    Applicant: LFB Biotechnologies
    Inventors: Christian Behrens, Christine Gaucher, Jean-Francois Prost, Jamila Najib
  • Publication number: 20090053233
    Abstract: The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of Fc?RIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma.
    Type: Application
    Filed: December 14, 2005
    Publication date: February 26, 2009
    Applicant: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Christophe De Romeuf, Christine Gaucher, Jean-Luc Teillaud, Jean-Francois Prost